Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Corixa Corporation
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
A histologically confirmed diagnosis of follicular lymphoma, Grade I, II, or III (WHO/REAL Classification) (follicular, small cleaved; follicular, mixed small-cleaved and large-cell; or follicular large-cell lymphoma in the International Working Formulation).
Recurrent lymphoma after one or two qualifying therapy regimen(s).
A performance status of at least 70% on the Karnofsky Scale.
An absolute neutrophil count \> 1500 cells/mm3 and a platelet count \> 100,000 cells/mm3.
Adequate renal function and adequate hepatic function.
Bi-dimensionally measurable disease with at least one lesion measuring \> or equal to 2.0 x 2.0 cm (i.e., \> 4.0 cm2) by CT scan.
HAMA negative.
At least 18 years of age.
Give written informed consent by signing an IRB/ethics committee approved informed consent form prior to study entry.
You may not be if
Histological transformation to diffuse,large cell lymphoma
More than 1 course of rituximab
Disease better treated with limited field therapy
Involvement of \>25% of the intratrabecular marrow
Active infection
Significant cardiac disease
Prior ChemoRx, biological therapy, radiation Rx, or high dose systemic steroid therapy within 8 weeks
Prior radioimmunotherapy
History of another malignancy
HBsAg positivity
CNS involvement with lymphoma
Pregnant or nursing
Ascites by physical exam
Previous use of non-human monoclonal antibody therapy, known hypersensitive to murine proteins
Hydronephrosis
Radiotherapy to \>25% of the blood forming marrow
Prior stem cell transplant
Failed stem cell harvest
Clareo Health | A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's Lymphoma
